Triptorelin and Relugolix: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Relugolix
Triptorelin
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both relugolix and triptorelin lower testosterone to help treat conditions like prostate cancer. Lowering testosterone can slightly affect the heart's electrical rhythm, causing something called QT prolongation. Using two of these medicines together could add up and make that effect a little stronger.
This is a theoretical concern, meaning it is based on how the drugs work rather than lots of real-world reports. Both drugs do similar jobs, so it would be unusual to take them at the same time. If you are prescribed both, don't stop anything on your own. Your care team can watch your heart rhythm and blood minerals to keep you safe.
Effect: Additive QT interval prolongation. Both relugolix (GnRH antagonist) and triptorelin (GnRH agonist) produce androgen deprivation, which can prolong the QT interval. Neither is a prodrug; this is a pharmacodynamic, not metabolic, interaction.
- Direction/magnitude: Additive QTc effect; magnitude not quantified.
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Avoid concurrent use when possible. Weigh benefit vs risk in congenital long QT, CHF, or electrolyte disturbance. If combined, correct and avoid hypokalemia/hypomagnesemia and consider periodic ECG and electrolyte monitoring.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
When relugolix is given together with medications that prolong the QT interval, the effects on the QT interval are additive. The androgen deprivation produced by GnRH agonists/antagonists can itself lengthen the QT interval. In patients who have congenital long QT syndrome, congestive heart failure, or recurrent electrolyte abnormalities, as well as in those receiving agents recognized to prolong the QT interval, weigh whether the benefits of androgen deprivation therapy such as relugolix are greater than the possible risks 1. Where feasible, do not use relugolix alongside QT prolonging agents. Should combined use be necessary, refrain from using medications that produce electrolyte abnormalities (that is, hypokalemia or hypomagnesemia) 2, correct any electrolyte abnormalities, and consider intermittent monitoring of ECGs and electrolytes 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
These are both androgen-deprivation therapies, so they are rarely prescribed together, and clinicians generally avoid combining QT-prolonging agents when possible. If your team decides you need both, they can manage this safely.
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
- Your team may check ECGs and blood electrolytes (potassium and magnesium) periodically and correct any imbalances.
- Tell your care team if you have a heart rhythm problem, heart failure, or a family history of long QT syndrome.
- Report symptoms like fainting, palpitations, or dizziness right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In an analysis of male patients on androgen deprivation therapy (ADT) using individual case safety reports from VigiBase, the international pharmacovigilance database, investigators identified 184 cases of acquired long-QT syndrome (aLQTS) and/or torsades de pointes (TdP; 11% of cases fatal), along with 99 cases of sudden death linked to ADT. The majority of aLQTS/TdP cases (62%) and sudden death cases (88%) tied to ADT occurred in the absence of other agents recognized to raise TdP risk; nevertheless, use of 1 drug and of 2 or more drugs carrying conditional, possible, or known TdP risk was noted in a portion of aLQTS/TdP events (23% or 43%) and sudden death events (18% and 22%). The agents regarded as ADTs comprised abiraterone, gonadotropin-releasing hormone agonists and antagonists, nonsteroidal androgen receptor inhibitors indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism. Among the 10 ADTs assessed, 7 showed a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death, namely leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The median patient age was about 76 years, and the median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients were receiving ADT mainly for prostate cancer, with some treated for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%); 17% were receiving ADT combination therapy 3.
Common questions
Can I take Triptorelin and Relugolix together?
Combining relugolix and triptorelin can add up to prolong the heart's QT interval, so this pairing is usually avoided; if you are on both, keep taking them as directed and let your care team monitor your ECG and electrolytes. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Triptorelin and Relugolix interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Triptorelin and Relugolix interaction managed?
These are both androgen-deprivation therapies, so they are rarely prescribed together, and clinicians generally avoid combining QT-prolonging agents when possible. If your team decides you need both, they can manage this safely. Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Your team may check ECGs and blood electrolytes (potassium and magnesium) periodically a… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Triptorelin or Relugolix need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ORGOVYX oral tablets, relugolix oral tablets. Sumitomo Pharma America, Inc (per FDA), Marlborough, MA, 2025. DailyMed
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
Keep reading about Relugolix
Keep reading about Triptorelin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist